Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis?


  • Funding sources: none.

  • Conflicts of interest: J.R.I., none declared; A.V.A. has received departmental research funding from Leo Pharma, Abbott and Schering Plough; V.P. has received departmental educational grants from MSD (Merck), Janssen and Basilea.

No abstract is available for this article.